spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

Biotechpharma


VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.

"The THEVAX HBV vaccine has been developed employing our company patented technology platform, which has enabled us to proceed from process development into cGMP production in a much shorter period of time. We are pleased to partner with Biotechpharma as our CDMO for cGMP manufacturing of our molecule entering clinical trials. Biotechpharma's excellent track record, expertise and capabilities to timely deliver a high quality product will play a significant role in the success of this program," says KinKai (Ben) Hwang, CSO of TheVax Genetics Vaccine CO., Ltd.

"We are delighted to be working with TheVax Genetics Vaccine CO on this exciting project and with great enthusiasm look forward to seeing it enter clinical trials," comments Vladas Bumelis, CEO of Biotechpharma. "Biotechpharma is well positioned to facilitate successful process transfer and manufacture of HBV vaccine in rapid time-frames, with focus on high quality and excellence in service."

About TheVax Genetics Vaccine CO., Ltd


TheVax Genetics Vaccine CO. Ltd is a publicly traded Taiwan-based company engaged in development of human vaccines. The Company's main products include therapeutic monovalent vaccines TVGV-1 and multivalent vaccines TVGV-2 for treatment of cervical cancer and precancerous lesions, and therapeutic vaccines TVGV-HBV for treatment of Hepatitis B.

www.vaxgenetics.com.tw

About Biotechpharma UAB


Biotechpharma UAB is a leading biopharmaceutical CDMO providing fully integrated process development and GMP manufacturing services globally. Biotechpharma has extensive experience in the production of new biological entities, having 150 employees at its state-of-the-art facility in Vilnius, Lithuania.

www.biotechpharma.lt

Related Links

http://www.biotechpharma.lt

http://www.vaxgenetics.com.tw
https://www.prnewswire.com/news-releases/thevax-genetics-vaccine-co-ltd-and-biotechpharma-uab-to-collaborate-on-cgmp-production-of-thevax-hbv-vaccine-300638279.html
email bd@biotechpharma.lt
web www.biotechpharma.lt
email Mokslininku st. 4. LT-08412 Vilnius, Lithuania
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI Clinical Services Announces New Facility Dedicated to Clinical Trial Returns

Philadelphia, USA – October 15, 2018. Leading international pharmaceutical outsourcing services provider PCI Clinical Services (PCI) has announced the completion of a dedicated Returns Management facility at its Clinical Services Center of Excellence at Bridgend, UK. PCI provides a full service Returns Management service for clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a clinical study. Returning and reconciling Investigational Medicinal Product (IMP) on completion of a study is a critical part of a Clinical trial and can require complex reverse logistics. Trial outcomes can be impacted if Returns are not processed efficiently and precisely.
More info >>


White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement